Diabetes mellitus - drugs Flashcards
Gestational diabetes mellitus - treatment strategies
- dietary modification
- exercise
- insulin replacement (if lifestyle modification fails)
insulin preparations - side effects
- hypoglycemia
- rare hypersensitivity reactions
- lipodystrophy - rare
insulin preparations - rapid acting - drugs?
- aspart
- Lispro
- Glulisine
insulin preparations - short acting - drugs?
regular
insulin preparations - intermediate acting - drugs?
NPH
insulin preparations - long acting - drugs?
- Detemir
2. Glargine
insulin preparations - rapid acting - duration?
2-5h
insulin preparations - short acting - duration?
4-8h
insulin preparations - intermediate acting - duration?
8-12
insulin preparations - long acting - duration?
16-24
insulin preparations - short acting - clinical use
- type 1 DM
- type 2 DM
- Gestational DM
- DKA (IV)
- hyperkalemia (+glucose)
- stress hyperglycemia
Oral hypoglycemic drugs - classes
- Biguanides
- Sulfonylureas
- Glitazones/thiazolidinediones
- GLP-1 analogs
- DPP-4 inhibitors
- Amylin analogs
- SGLT-2 inhibitors
- α-glucosidase inhibitors
- Meglitinides
Oral hypoglycemic drugs -biguanides drugs?
metformin
metformin action
exact mechanism unknown 1. Decreased gluconeogenesis 2. increased glycolysis 3. increased peripheral glucose uptake (increased insulin sensitivity)
metformin clinical use
first-line therapy in type 2 DM (causes modest weight loss)
metoformin - side effects
- GI upset
2. lactic acidosis (in renal failure)
metoformin is contraindicated in …(and why)
renal insufficiency
because of lactic acidosis
sulfonylureas - drugs?
first generation: chlorpropamide, tolbutamine
seond generation: glimepiride, glipizide, glypuride
sulfonylureas - second generation drugs (and HT)
- glimepiride –> high HT
- glipizide –> low HT
- glypuride –> high HT
sulfonylureas toxicities
- increased risk of hypoglycemia in renal failure
- first generation: disulfiram like reaction
- second generation: hypoglycemia
- Weight gain
Glitazone/thiazolidinediones - drugs
- pioglitazone
2. rosiglitazone
Glitazone/thiazolidinediones - mechanism of action
increased insulin sensitivity in peripheral tissue. Binds PPAR-γ nuclear transcription regulator
Glitazone/thiazolidinediones - clinical use
Used in monotherapy in type 2 DM or combined with other agents
Glitazone/thiazolidinediones - toxicity
- weight gain
- edema
- hepatotoxicity
- Heart failure
- increased risk for FRUCTURES
GLP-1 analogs - drugs
- exenatide
2. Liraglutide
GLP-1 analogs - mechanism of action
- increase glucose depended insulin release
- decrease glucagon release
- decrease gastric emptying
- increase satiety
GLP-1 analogs - clinical use
type 2 DM
GLP-1 analogs - toxicities
- nausea
- vomiting
- pancreatitis
- modest weight loss
DDP-4 inhibitors - drugs
- GLIPTIN
1. Linagliptin
2. Saxagliptin
3. Sitagliptin
DDP-4 inhibitors - mechanim of action
inhibits DPP-4 enzyme that deactivates GLP-1
- increase glucose-dependent insulin release
- decrease glucagon release
- decrease gastric emptying
- increase satiety
DDP-4 inhibitors - clinical use
type 2 DM
DDP-4 inhibitors - toxicities
Mild urinary or respiratory infections
wight neutral
Amylin analogs - drugs
Pramlintide
Amylin analogs - mechanims of action
- decrease gastric emptying
2. decrease glucagon
Amylin analogs - clinical use
- type 1 DM
2. type 2 DM
Amylin analogs - toxicities
- hypoglycemia (in setting of mistimed prandial insulin)
- nausea
- diarrhea
SGLT-2 inhibitors - drugs
- GLIFLOZIN
1. Canagliflozin 2. dapagliflozin 3. empagliflozin
SGLT-2 inhibitors - mechanims of action
Block reabsorption of glucose in proximal convoluted tubule
SGLT-2 inhibitors - clinical use
Type 2 DM
SGLT-2 inhibitors - side effects
- Glucosuria
- UTIs
- vaginal yeast infection
- hyperkalemia
- dehydration (orthostatic hypertension)
α-glcosidase inhibitors - drugs
- acarbose
2. Miglitol
α-glcosidase inhibitors - toxicities
GI disturbances
α-glcosidase inhibitors - clinical use
used as monotherapy in type 2 DM or in combination
α-glcosidase inhibitors - mechanims of action
inhibit intestinal brush - border α-glcosidase –> delayed carbohydrate hydrolysis and glucose absorption –> decrease postprandial hyperglycemia
diabetes mellitus drug with vaginal yeast infection as side effect
SGLT-2 inhibitors (Canagliflozin)
diabetes mellitus drug with mild respiratory or urinary infection as side effect
DDP-4 inhibitors (linagliptin, saxagliptin, sitagliptin)
diabetes mellitus drug that binds to PPAR-γ nuclear transcription
Glitazones/thiazolidinediones (pioglitazone, rosiglitazone)
Meglitinides - drugs
- Glinide
1. Nateglinide
2. Repaglinide
Meglitinides - clinical use
used as monotherapy in DM 2 or combined with metformin
Meglitinides - side effects
- weight gain
2. increased risk for hypoglycemia in renal failure
oral hypoglycemic drugs - drugs administrated through SC injection
- GLP-1 analogs
2. Amylin analogs
insulin in DKA
IV regular (HT –> 5 mins)
before prescribe SLGT-2 inhibitors
check renal function
treatment of severe hypoglycemia
IM glucagon in nonmedical setting (if glucagon is not available –> buccal or sublingual glucose
IV dextrose in medical setting
if mild hypoglycemia –>oral glucose (eg. juice)
hyperkalemia - treatment
potassium exhange resins (eg. sodium polystyrene sulfonate) –> excrete potasium from the body (through stools) by exchange it with sodium
insulin in DM2 - when / GOAL
added if the patient is not controled with oral hypoglycemic agens
HgA1c under 7%
glargine vs NPH insulin regarding steady state of insulin
glargine is better
NPH is dosed twice a dday